Cell and animal studies indicate that gypenosides can effectively attenuate hepatic steatosis associated with MAFLD by concomitantly activating AMPK signaling and inhibiting the TLR4/NF-κB inflammatory pathway. The gene discussed is TLR4; the disease is Hepatic steatosis.